Radiotherapy benefits last a decade, breast cancer study reveals
Providing radiotherapy after surgery could prevent breast cancer from returning in the same place for up to 10 years, a long-term study suggests.
This protective effect is limited after a decade, when the risk of cancer recurrence is similar to that in those who have not received radiotherapy.
The findings provide a more complete picture of the long-term benefits of radiotherapy following breast cancer surgery, experts say.
Surgery followed by radiotherapy remains the standard care for women with early-stage breast cancer. Radiotherapy targets high doses of radiation to the breast to destroy any remaining cancer cells after removal of the tumour.
The Scottish Breast Conservation Trial, led by the University of Edinburgh, looked at 585 women who received treatment for early-stage breast cancer in Scotland – half received radiotherapy and half did not. The average follow-up period for patients was 18 years, with some cases followed for more than three decades.
After 10 years, 16 per cent of those who had radiotherapy had experienced the return of their cancer in the same location, compared with 36 per cent of those who did not have the treatment.
Despite a reduction in cancer recurrence, survival rates did not improve with radiotherapy treatment.
Average overall survival rates after 30 years were similar for those who received postoperative radiotherapy and those who did not – 19.2 years and 18.7 years, respectively.
There were fewer deaths from breast cancer among those who received radiotherapy than those who did not – 37 per cent versus 46 per cent. By contrast, there were more deaths from other cancers in the group who received radiotherapy – 20 per cent versus 11 per cent.
Understanding the long-term impact of radiotherapy is increasingly important, as improvements in the detection and treatment of early-stage breast cancer mean that patients are living longer, experts say.
The study, funded by Exact Sciences and the Breast Cancer Institute, part of NHS Lothian Charity, is published in the journal The Lancet Oncology: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00347-4/fulltext [URL will become active after embargo lifts].
The research team included experts from the Usher Institute and the Institute of Genetics and Cancer at the University of Edinburgh, Public Health Scotland, Queen Elizabeth University Hospital in Glasgow, and the Western General Hospital in Edinburgh.
Dr Linda Williams, from the University of Edinburgh’s Usher Institute and lead author, said: “This 30-year study marks the longest follow-up of postoperative radiotherapy in the treatment of early-stage breast cancer. Long-term studies like this, which go beyond 10 years of follow up, are crucial to fully assess the risks and benefits of treatments.”
Professor Ian Kunkler, from the University of Edinburgh’s Institute of Genetics and Cancer, said: “Our evidence suggests that radiotherapy protects against cancer returning in the same breast for up to 10 years. It supports the continued use of radiotherapy after breast-conserving surgery for most patients with early breast cancer. Like other anti-cancer treatments, radiotherapy loses its beneficial effects in the long term."
For further information, please contact: Jess Conway, Press and PR Office, 07979 446209, jess.conway@ed.ac.uk
Journal
The Lancet Oncology
Method of Research
Randomized controlled/clinical trial
Subject of Research
People
Article Title
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial
Article Publication Date
7-Aug-2024
No comments:
Post a Comment